A Retrospective Study to Assess Risk Factors for Hepatotoxicity of Nintedanib in Japanese Patients with Idiopathic Pulmonary Fibrosis
Latest Information Update: 13 Jul 2017
Price :
$35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 13 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society